Cargando…
Erratum to efficacy and safety of mecapegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer: a randomized, multicenter, active-controlled phase III trial
Autores principales: | Xu, Fengrui, Zhang, Yang, Miao, Zhanhui, Zeng, Xiaohua, Wu, Biao, Cai, Li, Liu, Jinping, Wang, Shusen, Hu, Xichun, Zheng, Wenbo, Chen, Zhiyue, Yang, Qing, Jiang, Zefei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290653/ https://www.ncbi.nlm.nih.gov/pubmed/32566597 http://dx.doi.org/10.21037/atm-2020-23 |
Ejemplares similares
-
Erratum to prophylaxis of breast cancer chemotherapy for bone marrow toxicity: more individualized and safer
por: Xu, Fengrui, et al.
Publicado: (2020) -
Prophylaxis of neutropenia with mecapegfilgrastim in patients with non-myeloid malignancies: a real-world study
por: Ma, Jun, et al.
Publicado: (2021) -
A new peg-filgrastim biosimilar, mecapegfilgrastim for primary prophylaxis of chemotherapy-related neutropenia is now available
por: Tirelli, Umberto, et al.
Publicado: (2020) -
Erratum to a right atrium metastasis of breast cancer after long-term endocrine therapy
por: Xu, Fengrui, et al.
Publicado: (2020) -
A multicenter, open-label, phase III study of Abcertin in Gaucher disease: Erratum
Publicado: (2018)